anti-WT1/HLA-A2 TCR T-cell therapy (Sangamo)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-WT1/HLA-A2 TCR T-cell therapy (Sangamo)
Drug Alias NameZFN genetically engineered T-cell therapy (Sangamo)TRBC-ZFNTRAC-ZFN
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocytes stimulantsWilms' Tumour 1 modulatorsHLA Class I Histocompatibility Antigen, A-2 alpha Chain modulators +[4] 
TargetsWilms' Tumour 1HLA Class I Histocompatibility Antigen, A-2 alpha Chain
Therapy Area/IndicationsLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSangamo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSangamo Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsLeukemia

Other Information

ATC CodeN/A
Related LinksN/A